Elizabeth E. Morgan

Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases

Scott J. Hecker, K. Raja Reddy, Maxim Totrov et al. · Journal of Medicinal Chemistry · 2015 · 388 citations · Full text

Klebsiella Pneumoniae, Pharmacotherapy, Antimicrobial Chemotherapy +22

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

Keith S. Kaye, Tanaya Bhowmick, Symeon Metallidis et al. · JAMA · 2018 · 298 citations · Full text

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

David C. Griffith, Jeffery S. Loutit, Elizabeth E. Morgan et al. · Antimicrobial Agents and Chemotherapy · 2016 · 78 citations · Full text

Healthy Adult Subjects, Pharmacotherapy, Antimicrobial Chemotherapy +19

T cell receptor peptide vaccination in rheumatoid arthritis: A placebo-controlled trial using a combination of V?3, V?14, and V?17 Peptides

Larry W. Moreland, Elizabeth E. Morgan, T. C. Adamson et al. · Arthritis & Rheumatism · 1998 · 73 citations

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients

J.S. Elborn, David E. Geller, Douglas Conrad et al. · Journal of Cystic Fibrosis · 2015 · 68 citations · Full text

Medicine, Levofloxacin Inhalation Solution, Pharmacotherapy +1